Romosozumab/CDP7851 for the treatment of osteoporosis
Ie-Wen Sim, Peter R Ebeling
Expert Review of Endocrinology & Metabolism | ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD | Published : 2015
The authors were supported by Monash University and National Health and Medical Research Council of Australia. PR Ebeling has received research funding from Amgen, Merck, Novartis, and Eli-Lilly and honoraria from Merck, Amgen, Pfizer, ViiV Healthcare, and GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.